Key Takeaways Eli Lilly won EU marketing approval for Kisunla to treat early symptomatic Alzheimer's disease.The approval was backed by TRAILBLAZER studies showing Kisunla slowed cognitive and functional decline.The FDA also clears Inluriyo for ER , HER2- breast cancer with ESR1 mutations after prior endocrine therapy.Eli Lilly and Company (LLY) announced that the European Commission (EC) has granted marketing authorization to Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (A ...

Accessibility StatementSkip Navigation New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs INDIANAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to s ...

Accessibility StatementSkip Navigation An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:Â LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inl ...